Paper Title
REPURPOSING SIMVASTATIN LOADED WITH QUERCETIN IN A GUM ODINA BLENDED BIOPOLYMERIC VEHICLE: A NOVEL THERAPEUTIC STRATEGY FOR POLYCYSTIC OVARIAN SYNDROME (PCOS)

Abstract
Polycystic Ovarian Syndrome (PCOS) is a multifactorial endocrine-metabolic disorder that significantly impacts female reproductive health. The current pharmacological options, though symptomatic, often entail adverse effects and fail to address the syndrome's complex etiology. This study explores a novel drug delivery system utilizing biopolymeric microspheres composed of gum odina and sodium alginate for the synergistic delivery of Simvastatin and Quercetin, co-supplemented with zinc and magnesium. Microspheres were formulated using the ionotropic gelation technique and optimized based on entrapment efficiency, particle size, swelling index, and in vitro drug release kinetics. The optimized formulation was extensively characterized physicochemically (SEM, AFM, FTIR, XRD, DSC, TGA) and tested for antioxidant activity, biodegradability, and gastrointestinal stability. In vivo evaluation was performed in letrozole-induced PCOS Wistar rats to assess pharmacodynamic efficacy across hormonal, metabolic, inflammatory, and histomorphological markers. Results are expected to demonstrate significant improvement in ovarian morphology, hormonal balance, and systemic inflammation, thereby offering a safer, targeted, and more holistic alternative to existing PCOS therapies. This approach addresses the critical unmet need for long-term management of PCOS with minimal comorbid risk. Keywords - PCOS, Simvastatin, Quercetin, Gum Odina, Microspheres, Biopolymer, Drug Repurposing, In Vivo Study